Analysts Set Altimmune, Inc. (NASDAQ:ALT) Target Price at $20.00

Altimmune, Inc. (NASDAQ:ALT) has been assigned an average recommendation of “Moderate Buy” from the eight analysts that are covering the stock, Marketbeat Ratings reports. Two investment analysts have rated the stock with a hold rating, five have assigned a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $20.00.

A number of brokerages have commented on ALT. UBS Group initiated coverage on shares of Altimmune in a research note on Tuesday, November 12th. They set a “buy” rating and a $26.00 price target for the company. Evercore ISI upgraded shares of Altimmune to a “strong-buy” rating in a research report on Friday, August 9th. B. Riley restated a “buy” rating and issued a $20.00 price target on shares of Altimmune in a research report on Monday, August 12th. Finally, HC Wainwright restated a “buy” rating and issued a $12.00 target price on shares of Altimmune in a research note on Thursday, November 14th.

Altimmune Stock Performance

ALT stock opened at $8.68 on Monday. The firm has a 50 day simple moving average of $7.11 and a 200 day simple moving average of $6.93. Altimmune has a 52 week low of $2.50 and a 52 week high of $14.84. The stock has a market cap of $617.32 million, a P/E ratio of -5.60 and a beta of 0.09.

Altimmune (NASDAQ:ALT) last posted its quarterly earnings results on Tuesday, November 12th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.35) by $0.03. Altimmune had a negative net margin of 199,076.92% and a negative return on equity of 55.81%. The business had revenue of $0.01 million for the quarter. During the same quarter in the prior year, the firm earned ($0.39) earnings per share. Sell-side analysts predict that Altimmune will post -1.36 EPS for the current year.

Institutional Trading of Altimmune

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Price T Rowe Associates Inc. MD grew its position in shares of Altimmune by 13.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 15,238 shares of the company’s stock worth $156,000 after buying an additional 1,821 shares during the period. Creative Planning grew its holdings in shares of Altimmune by 20.5% in the 3rd quarter. Creative Planning now owns 18,411 shares of the company’s stock valued at $113,000 after buying an additional 3,132 shares during the period. CANADA LIFE ASSURANCE Co bought a new stake in Altimmune during the 1st quarter worth approximately $44,000. Charles Schwab Investment Management Inc. lifted its holdings in shares of Altimmune by 2.3% in the third quarter. Charles Schwab Investment Management Inc. now owns 211,626 shares of the company’s stock valued at $1,299,000 after purchasing an additional 4,772 shares in the last quarter. Finally, Larson Financial Group LLC bought a new position in shares of Altimmune during the 3rd quarter worth approximately $31,000. 78.05% of the stock is currently owned by institutional investors and hedge funds.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.